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Introduction: This narrative review provides an evidence-based summary of the various interventions in the 
management of Post Solid organ transplant patients who reported positive for COVID-19.   
Materials and Methods: For this systematic review, observational and experimental studies; conducted on Post- 
Organ transplant patients, either symptomatic or asymptomatic, who tested positive for COVID-19 were 
included. Only solid organ transplant patient studies were considered standard for this review type. The English 
version, both published and unpublished articles, from Dec 2019 to Aug 2020, were evaluated using Pubmed, 
Google Scholar, Science direct, Medrixv search engines. The articles with incomplete details about a transplant or 
covid management were excluded.  
Results: We selected 43 articles out of which 9 were retrospective studies, 2 were cohort studies, one was an 
experimental study, and 31 were case studies. According to the literature review, effective management therapy 
includes the withdrawal of immunosuppressive drugs, increase/ constant steroid dose, and regimen containing 
HCQ, interleukin inhibitor, and one antiviral drug especially remdesivir proved to be the most effective among 
all. In others, administration of IV immunoglobulins/convalescent plasma therapy proved effective in various 
trials but related data is currently limited. While Lop/Rit, Interferons alpha, and oseltamivir trials are also given; 
these therapies didn’t prove to be much effective individually. 
Conclusion: More trials are required to find the effectiveness of Convalescent plasma therapy. It can be proved as 
an effective treatment in critical patients. IV immunoglobulins effectiveness should also be tested in critical 
patients and for this more experimental trials are needed. 
Keywords: COVID-19 treatment, organ transplant patient, management of COVID-19, solid organ transplant 
patients; effectiveness of various treatments in SARS-CoV-2. 
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Introduction 
 
In early December 2019, coronavirus disease rapidly 
swept across Wuhan, China. Due to its widespread 
transmission, it was declared a pandemic by WHO in 
January 2020.1 As this pandemic maintains to spread, 
statistics on the scientific characteristics and 
consequences of COVID‐19 are emerging throughout 
continents.2 The novel coronavirus has been found 
strikingly similar to the virus which causes severe 
acute respiratory syndrome (SARS) in its 
morphology.3,4 The symptoms of COVID-19 vary but 
commonly fever, dry cough, fatigue and, generalized 
weakness have been observed.5  
Our study is based on how COVID-19 manifests in 
patients with solid organ transplants. By analyzing 
data from 2008 for 104 countries, every year 100800 
solid organ transplants are performed worldwide: 
69400 are kidney transplants, 20200 are liver 
transplants, 3400 are lung transplants, 2400 are 
pancreas transplants and 5400 are heart transplants. 
The clinical findings, therapeutic approach, and 
consequences of COVID-19 in patients with solid 
organ transplants remain unknown.6 We collected data 
from different databases to conclude how COVID-19 
manifests in patients with solid organ transplants and 
how we can manage its progression and 
immunosuppression via effective treatment options.  
 
Materials and Methods 
 
The eligibility criterion of our study was researches 
related to COVID-19 management in solid organ 
transplant patients. We searched four databases 
PubMed, Google scholar, science direct, and medrixv 
for our systematic review from December 2019 till 
August, 2020. Original articles, retrospective studies, 
and case studies in English were selected. Search terms 
used were: COVID-19 treatment in organ transplant 
patients, management of COVID-19 in solid organ 
transplant patients, and effectiveness of various 
treatments in COVID-19 patients with organ 
transplants.  
Four reviewers reviewed the database separately. In 
the first step, articles were excluded based on the title. 
Those studies were excluded which were not related to 
the management of COVID 19 in organ transplant 
patients. In the second step, duplicate articles and 
articles based on abstract were removed. All the 
articles other than original, retrospective and case 
studies were excluded. In the third step, full-text 
articles were assessed and articles based on quality 
and incomplete data were removed. Articles with 
ambiguous information were reviewed by more than 
one author and then excluded after the final 
discussion. All studies based on experiments on 
animals, artificial intelligence, editorials, comments of 
authors were excluded. Articles in a language other 
than English were also excluded. Data were extracted 
by four authors individually and finally reviewed by 
one author. Data were extracted based on variables 
which include study type, number of patients, time 
since organ transplant, COVID-19 symptoms, and 
management of covid19 patients in organ transplant 
patients. 
 




For this systematic review, we searched four research 
engines. Out of 2454 articles initially acquired, only 43 
were selected in the final review based on the 
inclusion and exclusion criteria. Among these 43 
articles: 9 were retrospective studies, 2 were cohort 
studies, and 31 were the case series. We extracted the 
respiratory complications and management of Covid-
19 from these articles in the form of a table. We made a 
column for “Covid-19 respiratory complications” in 
which we mentioned all the changes that were 
observed in the lungs of the patient during the 
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progression of covid-19. “Covid-19 specific treatment 
column” represented the treatment strategies used by 
health care professionals specifically against covid-19. 
The next column was “management of 
immunosuppression in Covid-19 patients”, which 
represented the changes made in patient organ 
transplant immunosuppression regime while treating 
a patient for Covid-19. In the end, “outcome 
“represented the final result whether the patient 
survived or not. Either the patient is discharged or still 
hospitalized was also mentioned in this column. 
The results of COVID-19 treatment and 
immunosuppressive management have been 
summarized in the following sections: 
Covid-19 in Renal Transplant patients:  
Data retrieved from case reports and retrospective 
studies suggest that kidney transplant patients with an 
average age of 50, normally presented with fever, 
cough, and malaise and later on developed respiratory 
complications. Almost all of them had comorbidities 
but no association was found between them and the 
progression of COVID-19. Patients recovered with 
symptomatic treatment along with temporary 
amendments in the immunosuppressive regimen. 
COVID-19 specific and immunosuppression 
management in renal transplant patients is discussed 
in Table 1. 
 
 
Table 1: Management of COVID-19 in a patient with Renal transplants 






  in covid-19 
Outcome 





HCQ (200 mg) bid 
IV Fluids, Tocilizumab 
(324 mg) S/C , IVIG 
(0.3 g/kg dose) 
CyA withdrawn, oral 
steroid dose increased 
(methylprednisolone 
16 mg per day) 
 
Discharged 
home on day 22  
 
A. Lauterio et 
al.8 






100mg BID, HCQ 
(400mg BID), Broad 
spectrum Antibiotics, 
LMW heparin ,I/V 
tocilizumab (Single 
Dose) 
CSA and were 
withdrawn, while 
PRED was increased to 
40 mg daily. 
 










Interferon α  (5 million 
units daily, atomization 
inhalation) 
D/C all ISx, 
Methylprednisolone 
daily I/V, Oral Tac 
resumed 1/2 dose after 
5 days D11 oral TAC & 
MMF to their full pre-
illness dosage levels 
Discharged 













L of oxygen therapy 
through the nasal 
cannula.  

















TAC MMF was 
discontinued. 
MMF was recontinued 
after treatment  
 
Alive 
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C. Q. Santos et 
al.12 






Tocilizumab 1/14  
High-dose 
glucocorticoids 2/14  






antimetabolite 10/12  
Withdrawal of mTOR 
inhibitor 2/2  
Death 2/14 
 
F. Silva et al.13 Bilateral interstitial 
infiltrate 2/5 




No specific treatment 
2/5 
MMF suspension 4/5, 
AZA & CyA suspension 
1/5 












IL-6 receptor inhibitor 
2(4%), Convalesant 
plasma 1(2%) 
Tac reduction 17(33%) , 
MMF reduction 15(28%) 
held 24(44%) Additional 
steroid therapy5(9%) 
7 pt. died 
 
Ghaffari et al.45 Bilateral lung 
involvement with 
GCO/consolidation, 
pericardial or pleural 
effusion 
oseltamivir, HCQ,  
lop/rit,  ribavirin, 
favipiravir, covalescent 
plasma therapy, IVIG 
MMF/MPA 
discontinued, CNI dose 
reduced 
10 survived, 9 
died 














Uni/Bilateral lung  c ̅ 
GCO & consolidation, 
pleural & pericardial 
effusion 
HCQ, lop/Rit, suitable 
IV antibiotics, IVIG 
Doses reduced 4 survived, 8 
died 
Nair et al.48 Multifocal patchy 
opacities 
HCQ, azithromycin Antimetabolites 
stopped, Tac dec. 
8 survived, 3 
died 









Tac,everolimus stopped. Survived 
Devreese et 
al.26 
N/A HCQ MMF stopped, TAC/ 











MMF suspended Survived 
Seminari et 
al.30 
Interstitial lesions NIL unchanged Survived 
 
Covid-19 in Lung Transplant patients 
Four case studies were screened for progression of 
COVID-19 in lung transplant patients. Average time 
since transplant was found to be 36 months. Patients 
with an average age of 53 years usually presented with 
fever and cough. Most of them developed respiratory 
complications and required oxygen support. One of 
the patients developed graft dysfunction leading to 
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death due to COVID-19 complications and secondary 
bacterial infection. Patients with different 
immunosuppressive therapy presented with different 
severity of disease which is suggestive of the fact that 
immunosuppressive regimen; especially steroids may 
play their part in the progression of the disease. In 
nearly all of the patients with symptomatic disease, 
immunosuppressive therapy was altered while no 
change was made in the regimen for patients without 
any symptoms. Covid-19 specific and 
immunosuppression management in lung transplant 
patients is discussed in (Table 2).    
 
Table 2: Management of COVID-19 inpatient with  LUNG transplant 






Typical patchy bilateral 
GGO 3/4, Patchy 
unilateral GGO 1/4 
HCQ + 
methylprednisolone 4/4 
Anakinra and remdesivir 
1/4 









X-ray showed no 
infiltrates 
Not specific No change Discharged 
N. Desmazes-
Dufeu et al.17 
GGO in lower lobes & 
subpleural linear 
consolidations 1/2 
N/A Mycophenolate was 
discontinued & MMF 











agent held(n: 6), 
No change:(n:2)  
died: 2 
Survived:6 









Covid-19 in Heart Transplant patients 
Studies suggest that patients with heart transplants; 
median age 56 years presented with common 
symptoms of COVID-19: fever, dry cough, and GIT 
disturbances. One retrospective study and four case 
studies were extracted. Nearly all of the patients were 
hypertensive and their antihypertensive treatment was 
continued along with reduced immunosuppressive 
therapy. Patients who did not survive usually 
presented with worsening symptoms and required 
intubation. The modifications in immunosuppression 
and COVID-19 specific treatment have been presented 
in Table 3. 
 















clazakizumab (anti-IL-6) 25 
mg in 50 mL normal saline, 
given over 30 minutes. 









less than 94  






















EVL & MMF discontinued, 
Tac/ CyA continued oral 
methyl pred Cont. 
19 survived, 
7 died  










CNIs not modified, mTORi 






NIL HCQ  Pred increased CsA 
adjusted several times. 
survived 
 
Covid-19 in multiple transplant patients 
There are 2 case reports, one with kidney-liver 
transplant and the other with the kidney-pancreas 
transplant. The intensity of the disease is not affected 
by the time of transplant in any study. The 
maintenance of immunosuppressive treatment is 
according to the severity of Covid-19. Fever, cough, 
and shortness of breath are disclosed as common 
symptoms. Diabetes and hypertension are common in 
these patients. ARBs and B-blockers are used by and 
large to treat comorbidities.  Covid-19 specific and 
immunosuppression management in multiple 
transplant patients is discussed in Table 4. 
 
Table 4: Management of COVID-19 inpatient multiple organ transplant 











MPA and Tac discontinued, 





BL GGO HCQ.  TAC stopped. died 
 
Covid-19 in Liver Transplant patient 
There are 5 case reports about patients with liver 
transplants. There is no significant impact of time of 
transplant on the severity of Covid-19. Most of the 
studies find fever, cough, fatigue, and headache as 
general symptoms. All patients were previously on 
immunosuppression treatment which was managed 
according to the intensity of covid-19 in them. 
Hepatitis B, Jaundice, splenomegaly, diabetes, and 
hypertension are reported as common comorbidities 
and are effectively treated. Covid-19 specific and 
immunosuppression management in liver transplant 
patients is discussed in Table 5. 
 
 
Table 5: Management of COVID-19 inpatient with Liver transplant 
Author Covid19 respiratory 
complications 
Covid19 specific treatment Immunosuppression 
management 
outcome 
Modi et al.29 NIL HCQ MMF stopped. Tac dec.  survived 
Hammami et 
al.28 
GGO AZM, HCQ, tocilizumab, N/A survived 
Zhong et al.31 Bilateral patchy 
GGO   
Oseltamivir phosphate Tac suspended survived 




Tac, MMF halved  
 
Died 
De Gottardi et 
al.33 
BL subpleural GGO Lopinavir, HCQ Sirolimus decreased survived 
 
Covid-19 in Variable Transplant patients 
There are 2 case reports, 4 retrospective studies, 1 
experimental study, and 1 cohort study.  Fatigue, 
myalgia, and fever are described as general symptoms 
in most of the studies. The regime of patients is 
modified according to the degree of infection and the 
condition of the immune system. Diabetes, 
hypertension, CVDs, and cirrhosis are outlined as 
common comorbidities. ARBs, ACE-i, and insulin are 
repeatedly used to treat comorbidities. Covid-19 
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specific and immunosuppression management in 
variable transplant patients is discussed in Table 6. 
 
 
Table 6: Management of COVID-19 inpatient with solid organ transplant (variable) 



















MMF held, Tac 
reduced, PRED 




NIL NIL Supportive care No change Survived 
NIL NIL Supportive care No change Survived 
NIL NIL Supportive care No change Survived 
Funget 









 All survived 
Fernand
ez Ruiz 
et al.44  
NIL NIL Lop/rit, HCQ Reduction of tac, 
D/C MPA, pred 
6 survived, 
2 died 
NIL NIL Lop/rit, HCQ Converted from 



































 HCQ:3 No specific: 9 
Azithromycine: 11 
No change :13 




















interferonalpha, Anakinra  
Antimetabolite 























None 10 (31%) 
 
For 32 indoor patients 









ISx changed 22 
(69%) ; MMF/AZA 
recepients 19 (71%) 
 held (50%) or 
reduced (29%). 
CNI in 1 (4%); 
mTOR inhibitors 
held 3 (100%); 
Belatacept deferred 
in 2 out of 3 
patients  
23 (72%)  
discharged; 
Five (16%)  
died; 
4 (36%) still 
hospitalized 
 





infiltrates in 13 
Pt. (68.4%); 




infiltrates in 13 
Pt. (68.4%); 
bilateral in 12 
of them 
(63.1%). 
HCQ 11/19; Lop/rit 2/19 
IFN-b 2/19  
TCZ 2/19 
No Sp. treatment (7/19) 
 
Reduced MMF in 
2/19 
EVE in 2 /19 
No change 16/19 
 
the patient 





There is solid evidence that management of 
immunosuppressive therapy in SOT patients stays the 
focal point of COVID-19 treatment. In all of the SOT 
patients who presented with COVID-19 complications, 
immunosuppressive therapy was transiently modified, 
usually halted or reduced. Many times this alone 
proved effective. HCQ proved to be the mainstay of 
COVID- specific treatment. Azythromycin was 
synergistically used along HCQ in lowering a viral 
load. Among antivirals, remdesivir was most 
competently used and it proved productive whereas 
lopinavir/ritonavir didn’t prove to be effective. 
Interleuikin inhibitor, Tociluzumab was frequently 
used however nothing at this point can be predicted 
about its efficacy. Scarce evidence is available on the 
use of convalescent plasma therapy, however, in some 
critical cases, it proved to be the life-saving option. The 
most effective management therapy in severe cases 
includes the withdrawal of immunosuppressive drugs, 
increase/ constant steroid dose and regimen 
containing HCQ, interleukin inhibitor, and one 




COVID-19 has been considered lethal for patients who 
have gone through a solid organ transplant. However, 
our retrieved data suggests that decreasing the 
immunosuppression regimen and increasing the 
steroids along with an appropriate dose of COVID-19 
specific medicines can result in 70 to 80 percent 
efficacy.  
Antivirals like remdesivir have shown positive results 
which may be due to their relatively non-toxic effects 
and less drug-drug interaction. The use of lop/rit for 
treating COVID-19 has been discouraged by recent 
studies. In a case report by Jiao-Feng et al. lop/rit 
treatment of a patient with a liver transplant resulted 
in multiple organ failure and mortality.49 
Hydroxychloroquine combined with lop/rit must be 
keenly tracked due to their known hepatotoxic 
effects.50 Data from different studies reveal that 
hydroxychloroquine can be looked after as a potential 
treatment option for COVID-19. However, according 
to a recent study, Hydroxychloroquine along with 
azithromycin can adversely affect the cardiac 
conduction pathways leading to arrhythmias so it is 
advisable to closely monitor the ECGs of patients 
especially if they have cardiac comorbidities.51  
The use of interleukin blockers like tocilizumab as a 
treatment option for COVID-19 is based on the belief 
that interleukins, especially interleukin-6, are the 
inflammatory substance resulting in lung damage. 
However, in a case series by Marcus R et al. the 
mortality rate of organ transplant patients who 
received tocilizumab was significantly higher than the 
patients who were treated without tocilizumab.52 
Therefore, building a shred of strong evidence about 
interleukin blockers as a possible treatment option for 
Covid-19 demands more studies.  
The emergence of COVID-19 has also reevaluated the 
effectiveness of historic convalescent plasma 
transfusion (CPT) which may reduce the mortality rate 
in critically ill patients. There is only a shred of the 
limited evidence available on it till now and multiple 
clinical trials are still ongoing. The convalescent 
plasma (CP) strategy is currently being used for 
prophylaxis as well as for the treatment of contagious 
diseases since the early 20th century.53 Apheresis is the 
procedural methodology to obtain blood plasma, 
based on continuous centrifugation of blood from 
donors (who are potentially recovered from the 
disease).54 A study by Shen et al showed 5 critically ill 
SARS CoV 2 infected patients recusant to antivirals, 
received Convalescent plasma therapy. After 
transfusion the fever settled down within 3 days, 
PaO2/FiO2 raised and PCR became negative within 
12 days.55 Another study conducted by Duan et al. 
showed the results from 10 severe cases who received 
one dose of CP leading to the disappearance of 
viremia in 7 days and clinical symptoms readily 
improved within 3 days.56 Thus, the administration of 
convalescent plasma is a potentially effective strategy 
with promising evidence on the improvement of 
clinical symptoms and with no side effects reported till 
now. 
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IVIg; a pooled normal IgG having both immune-
modulation and immune substitution effects, is 
obtained from the blood of healthy donors.57 It can 
elicit passive immunity and is an ideal option for the 
management of COVID patients. IVIG is considered to 
target cytokine storms in severe COVID‐19 patients.  
In a study, Mohtadi et al reported five critically ill 
SARS-CoV 2 infected patients for whom IVIG was 
administrated, which prevented the further downturn 
of symptoms. A high-dose IVIG (0.3–0.5 g/kg) was 
given to all patients for consecutive five days. Overall 
the patients’ response was satisfactory and they were 
discharged from the hospital after complete recovery.58 
Another study by Cao et al reported 3 patients with 
critical Covid-19 conditions. They were given high-
dose intravenous immunoglobulin (IVIg). They also 
recovered promptly and were discharged.59 Keeping in 
mind its potency in modulating immune inflammation 
high-dose IVIg could be considered an encouraging 
alternative at the initial stage of the clinical downturn 
of patients with COVID-19. Further experiments 
should be conducted to infer the effectiveness of this 
approach.  
Limitations of this study include that up till now a 
finite number of studies have been conducted on the 
management of SARS-CoV 2 disease in organ 
transplant patients. We excluded articles of all 
languages except English. We considered only the 
Solid-organ type of transplant, other types of 
transplant articles are not considered. Limited data of 
patients were available as most of the case report 
studies were found. Thus, more experiments are still 
required to assess the potency of different 
management strategies in Solid organ transplant 




To sum up, in organ transplant patients with covid-19, 
withdrawal of immunosuppressive drugs revealed 
considerably good results. Hydroxychloroquine 
manifested results up to the mark. But Lopinavir and 
Ritonavir were found to be non-productive. 
Intravenous Immunoglobulin and Convalescent 
plasma therapy were also used.  Amidst all medicinal 
techniques, convalescent plasma transfusion is found 
to be a potentially effective strategy. But multiple 
clinical trials are still required to infer the efficacy of 
this treatment.   
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